Results 161 to 170 of about 55,779 (204)
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Review of Anti-Infective Therapy, 2021
Introduction: Dengue virus is a global health threat, with approximately 390 million dengue infections annually. Efficient vaccines for dengue prevention are currently lacking. This review aims to summarize the current progress in dengue vaccine development.Area covered: This article discusses recent dengue vaccine developments based on the published ...
Yu-Te Tsai +2 more
exaly +3 more sources
Introduction: Dengue virus is a global health threat, with approximately 390 million dengue infections annually. Efficient vaccines for dengue prevention are currently lacking. This review aims to summarize the current progress in dengue vaccine development.Area covered: This article discusses recent dengue vaccine developments based on the published ...
Yu-Te Tsai +2 more
exaly +3 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2008
Dengue is the most important mosquito borne virus infection in the tropics. Based on the effects of global warming, it is expected that dengue epidemic areas will further expand in the next decades unless effective and affordable vaccines are made available soon.
Scott B. Halstead, David W. Vaughn
openaire +3 more sources
Dengue is the most important mosquito borne virus infection in the tropics. Based on the effects of global warming, it is expected that dengue epidemic areas will further expand in the next decades unless effective and affordable vaccines are made available soon.
Scott B. Halstead, David W. Vaughn
openaire +3 more sources
The Lancet, 2002
Every year there are several hundred thousand acres of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) resulting in thousands of deaths. The only method currently available to prevent dengue infections is the control of Aedes aegypti the mosquito vector. This approach has proved expensive and mostly unworkable.
Scott B, Halstead, Jacqueline, Deen
openaire +2 more sources
Every year there are several hundred thousand acres of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) resulting in thousands of deaths. The only method currently available to prevent dengue infections is the control of Aedes aegypti the mosquito vector. This approach has proved expensive and mostly unworkable.
Scott B, Halstead, Jacqueline, Deen
openaire +2 more sources
Dengue vaccines: implications for dengue control
Current Opinion in Infectious Diseases, 2017Purpose of review Dengue, the most common arbovirus, is an increasingly significant cause of morbidity worldwide. After decades of research, an approved tetravalent dengue vaccine is finally available. Models constructed using recently available vaccine efficacy data allow for a data-driven discussion of the potential impact of
Matthew L, Robinson, Anna P, Durbin
openaire +2 more sources
A Review on Dengue Vaccine Development [PDF]
Vaccines, 2020 Dengue virus (DENV) has become a global health threat with about half of the world’s population at risk of infection. Although the disease caused by DENV is self-limiting in the first infection, the antibody-dependent enhancement (ADE) effect increases the mortality in the second infection with a heterotypic virus.
Sheng-Qun Deng, Hong-Juan Peng
exaly +4 more sources
Vaccine, 2017
The vaccine against Dengue virus (DENV), Dengvaxia® (CYD), produced by Sanofi-Pasteur, has been registered by several national regulatory agencies; nevertheless, the performance and security of this vaccine have been challenged in a series of recent papers.
Ruth Aralí, Martínez-Vega +3 more
openaire +2 more sources
The vaccine against Dengue virus (DENV), Dengvaxia® (CYD), produced by Sanofi-Pasteur, has been registered by several national regulatory agencies; nevertheless, the performance and security of this vaccine have been challenged in a series of recent papers.
Ruth Aralí, Martínez-Vega +3 more
openaire +2 more sources
Expert Review of Vaccines, 2016 Dengue is a public health problem in the tropics and subtropics. There are several vaccine candidates in clinical development. However, there may be gaps in the new vaccine introduction after vaccine licensure before it becomes available in developing countries.
Jacqueline K Lim +2 more
exaly +3 more sources